<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03722940</url>
  </required_header>
  <id_info>
    <org_study_id>Bahtem WBAKHET</org_study_id>
    <nct_id>NCT03722940</nct_id>
  </id_info>
  <brief_title>Role of Magnesium in Pediatric Cochlear Implant</brief_title>
  <official_title>Combination of Magnesium Sulphate With Total Intravenous Anesthesia Optimized Surgical Field in Pediatric Cochlear Implant Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wahba bakhet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>bahteem specialized hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficiency of addition of magnesium sulfate to total intravenous anesthesia
      (TIVA) in optimizing the surgical field during pediatric cochlear implant surgery. Also its
      effects on the intraoperative evoked stapedial reflex thresholds (ESRT) and the
      intraoperative anesthetic requirements were evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sixty-six ASA I and II children (1-6 years) undergoing cochlear implantation under general
      anesthesia were enrolled in this double blind, randomized study. Children were randomly
      allocated into two equal groups. Children in Group M (magnesium sulphate group) received an
      iv bolus dose of magnesium sulfate 40 mg Kg-1 over 5 minutes before induction of anesthesia
      followed by 15mg Kg-1 h-1 infusion until the start of skin closure. Children in Group C
      (Control group) received equivalent volumes of isotonic saline solution over the same period
      instead of magnesium sulphate. Haemodynamic variables, quality of surgical field, ESRT and
      the intraoperative anesthetic requirements were recorded
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2014</start_date>
  <completion_date type="Actual">August 1, 2018</completion_date>
  <primary_completion_date type="Actual">May 30, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of surgical field</measure>
    <time_frame>at the end of the surgey</time_frame>
    <description>using Fromme's-Boezaart scale (0 to 5). A score of â‰¤ 2 was considered to be optimal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The operative time</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The anesthesia time.</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ESRT responses</measure>
    <time_frame>After insertion of the electrode and after reversal of any residual muscle relaxant (TOF response &gt; 0.9),</time_frame>
    <description>the surgeon assessed ESRT response at the basal, middle, and apical areas of the electrode array by visual monitoring of the stapedius muscle using direct microscopic examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>baseline, after surgical incision, Hypotensive period, after LMA removal and at recovery room admission.</time_frame>
    <description>beats per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean arterial blood pressure</measure>
    <time_frame>Intraoperative</time_frame>
    <description>mm Hg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anesthetic consumption</measure>
    <time_frame>Intraoperative</time_frame>
    <description>propofol and fentanyl requirement after the bolus</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Magnesium sulphate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group M</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Na CL 0.9%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>group C</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium sulphate</intervention_name>
    <description>Before induction of anesthesia; children in group M received an iv bolus dose of magnesium sulfate (Magnesium sulfate ampoule 1 gm/10 ml, Eipico, Egypt) 40 mg Kg-1 over 5 minutes followed by 15 mg Kg-1 h-1 ivi until the start of skin closure.</description>
    <arm_group_label>Magnesium sulphate</arm_group_label>
    <other_name>MGSO4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Na CL 0.9%</intervention_name>
    <description>Before induction of anesthesia; children in group C equivalent volumes of Na Cl 0.9% over the same period instead of magnesium sulphate.</description>
    <arm_group_label>Na CL 0.9%</arm_group_label>
    <other_name>isotonic saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA I and II children

        Exclusion Criteria:

          -  uncontrolled hypertension,

          -  diabetes mellitus,

          -  liver disease,

          -  kidney disease,

          -  heart disease,

          -  allergy to magnesium sulphate,
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 19, 2018</study_first_submitted>
  <study_first_submitted_qc>October 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2018</study_first_posted>
  <last_update_submitted>October 25, 2019</last_update_submitted>
  <last_update_submitted_qc>October 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Wahba bakhet</investigator_full_name>
    <investigator_title>Lectrure of anesthesia</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

